Compare WD & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WD | AVDL |
|---|---|---|
| Founded | 1937 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 2010 | 1996 |
| Metric | WD | AVDL |
|---|---|---|
| Price | $63.63 | $21.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $83.33 | $18.38 |
| AVG Volume (30 Days) | 257.9K | ★ 1.6M |
| Earning Date | 02-12-2026 | 03-02-2026 |
| Dividend Yield | ★ 4.10% | N/A |
| EPS Growth | ★ 20.18 | N/A |
| EPS | ★ 3.37 | N/A |
| Revenue | ★ $1,160,070,000.00 | $248,517,000.00 |
| Revenue This Year | $21.20 | $65.47 |
| Revenue Next Year | $10.20 | $30.88 |
| P/E Ratio | $19.41 | ★ N/A |
| Revenue Growth | 17.65 | ★ 79.88 |
| 52 Week Low | $58.60 | $6.38 |
| 52 Week High | $97.70 | $23.57 |
| Indicator | WD | AVDL |
|---|---|---|
| Relative Strength Index (RSI) | 51.39 | 57.12 |
| Support Level | $62.56 | $21.45 |
| Resistance Level | $66.47 | $21.60 |
| Average True Range (ATR) | 1.68 | 0.07 |
| MACD | 0.67 | -0.04 |
| Stochastic Oscillator | 63.91 | 51.22 |
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.